The Depo Provera MDL is gaining momentum. This mass tort consolidation under Judge M. Casey Rodgers in Florida now totals 289 active cases, up from 130 cases in early April 2025.
Federal courts have authorized direct MDL filings, eliminating slower transfer delays . In late May, Judge Rodgers held a key case management conference. She set deadlines for discovery and expert disclosures. Bellwether trial selection is already in progress.
Recent studies increased urgency. A 2024 BMJ study found that one year’s use of Depo‑Provera raised the risk of intracranial meningiomas by more than 5‑fold.. Other studies from the UBC and Medsafe confirmed links to spinal and brain tumors.
Plaintiffs allege Pfizer failed to warn consumers. Generic makers like Greenstone and Viatris have been dismissed, leaving Pfizer the main defendant. Records show Pfizer provided over 8 million pages of documents. With discovery underway and pilot cases set, the MDL is on track to reach first bellwether trials by late 2026. This fast‑tracking could influence future brain tumor claims and settlement negotiations.
